Biomedical subjects

Edith Collard

Publications and source records attributed to Edith Collard.

3 recordsLinked to original sources

PubMed2004

Continuous cold blood cardioplegia improves myocardial protection: a prospective randomized study.

BACKGROUND: To assess the influence on myocardial protection of the rate of infusion (continuous vs intermittent) of cold blood cardioplegia administered retrogradely during prolonged aortic cross-clamping. The end-points were ventricular performance and biochemical markers of ischemia. METHODS: Seventy patients undergoing myocardial revascularization for three-vessel disease were prospectively randomized to receive intermittent or continuous retrograde cold blood cardioplegia. Hemodynamic measurements were obtained using a rapid-response thermodilution catheter and included right ventricular ejection fraction, cardiac output, left and right ventricular stroke work index, and systemic and pulmonary vascular resistance. Blood samples were obtained from the coronary sinus before cross-clamp application and immediately after cross-clamp removal for determinations of lactate and hypoxanthine. RESULTS: The left ventricular stroke work index trend was significantly superior (p = 0.038) by repeated-measures analysis in continuous cardioplegia. Other hemodynamic measurements revealed a similar trend. The need for postoperative inotropic drugs support was reduced in continuous cardioplegia. The release of lactate in the coronary sinus after unclamping was 2.30 +/- 0.12 mmol/L after intermittent cardioplegia and 1.97 +/- 0.09 mmol/L after continuous cardioplegia (p = 0.036). The release of hypoxanthine was 20.47 +/- 2.74 micromol/L in intermittent cardioplegia and 11.77 +/- 0.69 micromol/L in continuous cardioplegia (p = 0.002). CONCLUSIONS: Continuous cold blood cardioplegia results in improved ventricular performance and reduced myocardial ischemia in comparison with intermittent administration.

Aged↗

PubMed2003

Ventricular assist devices.

PURPOSE OF REVIEW: Recent advances in technology as well as new indications for implantation have appeared in the field of ventricular assist devices. Progress has also been made in the understanding of the underlying mechanisms of myocardial recovery after ventricular assist device support. RECENT FINDINGS: Technological progress includes the development of fully implantable pulsatile and continuous flow pumps, either axial flow or centrifugal, for left ventricular and total heart assistance. Among the new indications for ventricular assist device support, the most important is the use of the device as permanent treatment for end-stage cardiac failure patients. Increased knowledge has been acquired regarding the effects of mechanical assistance and of unloading of the heart on haemodynamics, as well as on the cellular, molecular and electrophysiological characteristics of the failing heart. All these findings suggest that depressed myocardial function can sometimes recover with ventricular assist device therapy. Ventricular assist device support, however, still carries a high rate of complications: the device itself can fail, bleeding and thromboembolism are common, immunity is disturbed and the incidence of infection remains high. SUMMARY: In patients with end-stage heart failure, ventricular assist devices can be used as a bridge to transplantation or to recovery, but they are now also considered as a long-term myocardial replacement therapy. Which device is the most appropriate for each indication, however, remains to be defined. Even if the underlying mechanisms of myocardial recovery are progressively clarified, the use of ventricular assist devices as a bridge to recovery still has limited clinical success. Clinical trials with the fully implantable devices are in their early stages, but these pumps appear promising in terms of efficacy, reliability and complication rate, as well as being easy to implant. Because more patients will benefit from ventricular assist device placement in the future, anaesthesiologists must be prepared to manage patients undergoing ventricular assist device placement or presenting for noncardiac surgery while under ventricular assist device support.

Journal Article↗

PubMed2002

Off-pump coronary artery bypass grafting: a case-matched comparison of hemodynamic outcome.

OBJECTIVE: The objective of this study was to assess improved myocardial protection by performing coronary artery bypass grafting (CABG) on the beating heart. A case-matched study was conducted among patients who underwent CABG either on-pump (group 1), or off-pump (group 2). METHODS: Forty-five pairs of patients, having a similar clinical profile, were selected on the basis of five variables: age, gender, body surface area, ejection fraction, extent of coronary disease. Operative risk predicted by the The Society of Thoracic Surgeons national database was 1.80+/-0.35% in group 1, and 1.89+/-0.37% in group 2 (NS). Cold blood cardioplegia and 28 degrees C cardiopulmonary bypass were used in group 1. In group 2, beating heart coronary grafting was achieved with the Octopus 1 and 2 stabilizers. The average number of distal anastomoses was 2.8+/-0.1 in group 1 and 2.3+/-0.1 in group 2 (P=0.015). RESULTS: There was no significant difference among the groups regarding the trend in cardiac index, left and right ventricular stroke work indexes, and systemic and pulmonary vascular resistance indexes. However, heart rate trend was slower in group 2 (P=0.05). Pharmacological support was required in 65% of the patients in group 1, and in 33% in group 2 (P<0.001). The total amount of Dobutamine and/or Dopamine administered during the first 48 h was 3914+/-1306 gamma/kg in group 1 and 1645+/-697 gamma/kg in group 2 (P=0.049). Release of creatine kinase MB mass isoenzyme (CK-MB mass) was markedly reduced in group 2 (P<10(-4)). CONCLUSIONS: Hemodynamic outcome following off-pump CABG is similar to on-pump CABG but the need for inotropic support is significantly reduced and CPK-MB mass release is markedly lower.

Aged↗